Tango Therapeutics (TNGX) Appoints Robert Azelby to Board

Tango Therapeutics (TNGX) announced the appointment of Robert Azelby to its Board of Directors, effective June 23, 2026. The strategic addition aims to enhance the company's governance and leverage Azelby's deep industry expertise. Azelby brings over 25 years of experience in the biotechnology and pharmaceutical sectors, including senior leadership positions in commercial operations, corporate strategy, and business development. His background is expected to be instrumental as Tango Therapeutics advances its pipeline of precision oncology medicines. The appointment underscores Tango's commitment to strengthening its strategic oversight and clinical development efforts.